Carcinoma buccal mucosa treated with definitive hypofractionated accelerated radiotherapy: a retrospective analysis of treatment outcomes.

Autor:	Babu G; Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India., Ravikumar R; Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India., Rafi M; Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India., Sharafuddin Z; Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India., Shankar SA; Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India., George PS; Department of Cancer Epidemiology and Biostatistics, Regional Cancer Centre, Trivandrum, Kerala, India., Kainickal CT; Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India., Kunnambath R; Department of Radiation Oncology, Regional Cancer Centre, Trivandrum, Kerala, India.
Jazyk:	angličtina
Zdroj:	Singapore medical journal [Singapore Med J] 2023 Aug 17. Date of Electronic Publication: 2023 Aug 17.
DOI:	10.4103/singaporemedj.SMJ-2021-282
Abstrakt:	Introduction: Oral cancer is a major public health concern in India. Both conventional and altered fractionation radiotherapy schedules have been used in curative treatment of oral cancer. This study aimed to retrospectively evaluate the clinical profile and treatment outcomes of patients with carcinoma buccal mucosa who underwent treatment with definitive hypofractionated accelerated radiotherapy. Methods: A total of 517 patients treated from January 2011 to December 2016 were eligible for the analysis. All patients were treated with definitive hypofractionated accelerated radiotherapy schedule of 5,250 cGy in 15 fractions over 3 weeks. Survival estimates were generated using the Kaplan-Meier method. Results: At a median follow-up of 77.4 months, 473 (91.5%) patients attained complete remission with radiation therapy. The 5-year disease-free survival (DFS) and overall survival (OS) rates were 69% and 80.5%, respectively. The 5-year OS for stage I, II, III and IVa tumours was 80.3%, 84.4%, 81.4% and 73.7%, respectively, and the DFS was 75.7%, 73.2%, 69.6% and 60.2%, respectively. Age >50 years was found to be a significant factor affecting DFS (P = 0.026) and OS (P = 0.048) in multivariate analysis. Fifty-three (10.3%) patients developed osteoradionecrosis of the mandible. Conclusion: Excellent outcome could be achieved in less-aggressive, low-volume carcinoma of the buccal mucosa with radical accelerated hypofractionated radiotherapy. A radiotherapy schedule over a 3-week period is useful in high-volume centres. Competing Interests: None
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu